Literature DB >> 10391137

Inhibition of calcium ATPase by phencyclidine in rat brain.

M Pande1, J A Cameron, P J Vig, S F Ali, D Desaiah.   

Abstract

Phencyclidine (PCP) is a potent psychotomimetic drug of abuse and has profound effect on the functioning of the central nervous system (CNS). Many of the CNS functions are known to be mediated by calcium (Ca2+). In the present study we have investigated the effects of PCP on Ca2+ ATPase activity in rat brain both in vitro and in vivo. For in vitro studies, synaptic membrane fractions prepared from normal rat brain were incubated with PCP at different concentrations (25-100 microM) before the addition of substrate. For in vivo studies, rats were treated with a single moderate dose of PCP (10 mg/kg, i.p.) and animals were sacrificed at 1,2, 6 and 12 h after treatment. Ca2+ ATPase activity in synaptic membrane fractions was assayed by estimation of inorganic phosphate. PCP inhibited the Ca2+ ATPase in vitro in a concentration dependent manner with significant effect at 50 and 100 microM. A significant time-dependent reduction of the Ca2+ ATPase activity was evident in vivo. As early as 2 h after the treatment of rats with PCP the ATPase activity was significantly reduced. The reduction of Ca2+ ATPase observed even at 12 h after treatment suggesting a prolonged presence of the drug in the brain tissue. Further, kinetic studies in vitro indicated PCP to be a competitive inhibitor of Ca2+ ATPase with respect to the substrate, ATP. The present findings indicate that PCP inhibits synaptic membrane Ca2+ ATPase thus altering cellular Ca2+ homeostasis in CNS which may partially explain the pharmacological effects of the drug and/or its neurotoxicity.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10391137     DOI: 10.1023/a:1006911420745

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  30 in total

Review 1.  Modulation of NMDA and dopaminergic neurotransmissions by sigma ligands: possible implications for the treatment of psychiatric disorders.

Authors:  G Debonnel; C de Montigny
Journal:  Life Sci       Date:  1996       Impact factor: 5.037

2.  Postnatal phencyclidine treatment differentially regulates N-methyl-D-aspartate receptor subunit mRNA expression in developing rat cerebral cortex.

Authors:  R Sircar; P Follesa; M K Ticku
Journal:  Brain Res Mol Brain Res       Date:  1996-09-01

3.  Some effects of an hallucinogenic drug (phencyclidine) on neurohumoral substances.

Authors:  B E Leonard; S R Tonge
Journal:  Life Sci I       Date:  1970-10-15

4.  Chronic phencyclidine treatment decreases phencyclidine and dopamine receptors in rat brain.

Authors:  R Quirion; M A Bayorh; R L Zerbe; C B Pert
Journal:  Pharmacol Biochem Behav       Date:  1982-10       Impact factor: 3.533

5.  Interaction of phencyclidines with the muscarinic and opiate receptors in the central nervous system.

Authors:  J P Vincent; D Cavey; J M Kamenka; P Geneste; M Lazdunski
Journal:  Brain Res       Date:  1978-08-18       Impact factor: 3.252

6.  Phencyclidine block of calcium current in isolated guinea-pig hippocampal neurones.

Authors:  J M Ffrench-Mullen; M A Rogawski
Journal:  J Physiol       Date:  1992-10       Impact factor: 5.182

7.  Phencyclidine produces changes in NMDA and kainate receptor binding in rat hippocampus over a 48-hour time course.

Authors:  X M Gao; C A Tamminga
Journal:  Synapse       Date:  1996-08       Impact factor: 2.562

8.  Degenerative and axon outgrowth-altering effects of phencyclidine in human fetal cerebral cortical cells.

Authors:  M P Mattson; B Rychlik; B Cheng
Journal:  Neuropharmacology       Date:  1992-03       Impact factor: 5.250

9.  Serotonergic involvement in phencyclidine-induced behaviors.

Authors:  T Nabeshima; K Yamaguchi; M Hiramatsu; M Amano; H Furukawa; T Kameyama
Journal:  Pharmacol Biochem Behav       Date:  1984-09       Impact factor: 3.533

10.  PCP/NMDA receptor-channel complex and brain development.

Authors:  R Sircar; C S Li
Journal:  Neurotoxicol Teratol       Date:  1994 Jul-Aug       Impact factor: 3.763

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.